Tuberculosis: The Big Picture And Challenge of Drug-resistance
|
|
- Sherman Carroll
- 6 years ago
- Views:
Transcription
1 5 th APHL National Conference on Laboratory Aspects of Tuberculosis August 11-13, 2008 San Diego, California Tuberculosis: The Big Picture And Challenge of Drug-resistance RADM Kenneth G. Castro, M.D. Assistant Surgeon General, USPHS Director, Division of Tuberculosis Elimination National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention
2 Those who cannot remember the past are condemned to repeat it George Santayana, The Life of Reason, 1905
3 Excess TB Morbidity, U.S Conditions Deficient infrastructure HIV epidemic Immigration Institutional transmission MDR-TB Cantwell M, et al. JAMA 1994; 272:536
4 Profile of Selected HIV-related MDR TB Outbreak Investigations in U.S., Hospital Total Cases % HIV Infected % Deaths A B C D E F I J Prison Median Wks Dx to Death
5 Heatlthcare Worker Union and ACT-UP Demonstrations, 1991
6 Recommendations and Reports June 19, 1992 / 41(RR-11);1-48 National Action Plan to Combat Multidrug-Resistant Tuberculosis
7 U.S. Response to TB Resurgence National MDR-TB Action Plan & New Resources Improved Case Identification & Training Updated Diagnostic Labs, Real-time Drug Resistance, & Strain Fingerprinting Rebuilt Research Capacity Updated Infection Control & Rx Recommendations DOT & Improved Rx Completion 2HRZE plus 4HR
8 Effect of DOT on Drug Resistance & Relapse, Tarrant County, Texas* Percent Variable SAT DOT (01/80-10/86) (11/86-12/92) P value 1 0 Resistance Acq. Resistance <0.001 Total Relapses <0.001 During Rx MDR TB <0.001 * Weis, et al. N Eng J Med 1994;330:
9 TB Laboratory Standards Lab Tools AFB microscopy NAA Culture detection Culture identification 1 st -line DST 2 nd -line DST Max TAT* 24 hrs 48 hrs 14 days 21 days 30 days 4 weeks * Turn-around time (TAT) from specimen collection; for 2 nd -line DST from date of request
10 Reported TB Cases* United States, ** No. of Cases 28,000 26,000 24,000 22,000 20,000 18,000 16,000 14,000 12,000 10, Year *Updated as of April 23, 2008 ** Unpublished provisional data, not for citation 13,299
11
12 TB Case Rates,* United States, 2007** NY NJ MD D.C. CA AL AZ TX LA MS GA SC FL HI *Cases per 100,000. ** Unpublished provisional data, not for citation < 3.5 (year 2000 target) > 4.4 (national average)
13 Reported TB Cases by Race/Ethnicity* Native Hawaiian or Other Pacific Islander (<1%) United States, 2007** 83% in racial/ethnic minorities White (17%) American Indian or Alaska Native (1%) Asian (26%) Hispanic or Latino (29%) Black or African American (26%) *All races are non-hispanic. Persons reporting two or more races accounted for less than 1% of all cases. ** Unpublished provisional data, not for citation
14 Trends in TB Cases in Foreign-born Persons, No. of Cases 10,000 8,000 6,000 4,000 2,000 0 United States, * Percentage No. of Cases Percentage of Total Cases * Unpublished provisional data, not for citation
15 Countries of Birth of Foreign-born Persons Reported with TB United States, 2007* Other Countries (38%) Mexico (25%) Philippines (11%) Guatemala (3%) Haiti (3%) China (5%) India (7%) Viet Nam (8%) * Unpublished provisional data, not for citation
16 Global 9.2 million new TB cases, 1.7 million deaths in 2006 Estimated number of new TB cases (all forms) No estimate or more 80% of Global TB Cases in 22 Countries
17 Global New TB Cases/100,000 Population, 2006 World: case rates rising during 1990s, now stable or falling slowly Europe: case rates up by 40% during 1990s, now falling slowly Estimated new TB cases (all forms) per population No estimate or more Africa: case rates up by 200+% during 1990s, now falling slowly
18 Global Stop TB Strategy
19 By 2005 sustain or exceed by 2015 Detect 70% of new sputum smear (SS) + cases 2005 Global 60% Successfully treat 85% of these cases 2004 Global 84% By 2015 Reduce TB prevalence and deaths by 50% (relative to 1990) Reducing prevalence to 155 per 100, Global 217/100,000 Reducing deaths to 14 per 100, Global 24/100,000
20 the issue now confronting the nation is whether we will allow another cycle of neglect to begin or, instead, whether we will take decisive action to eliminate tuberculosis IOM
21 IOM Ending Neglect Recommendations: Eliminate TB in U.S. 1. Maintain control while adapting to declining incidence 2. Speed decline through increased treatment of latent infection 3. Develop new diagnostic, treatment, and vaccine tools 4. Increase U.S. engagement in global efforts 5. Mobilize support for elimination and monitor progress
22 Interrupting Chain of Transmission for Mycobacterium tuberculosis complex Active TB Source Treatment TB Disease Contact Infection Control Infection Treatment LTBI Secondary TB Cases
23
24 Prevalence of Tuberculosis Infection, U.S. Bennet DE, et al. Am J Resp Crit Care Med 2008;177: % LTBI Prevalence Estimated No. x Population (95% CI) Million (95% CI) All 4.2 ( ) 11.2 ( ) U.S.-born 1.8 ( ) 4.1 ( ) Foreign-born 18.7 ( ) 6.9 ( ) Poverty Index ( ) 6.5 ( ) Poverty Index < ( ) 2.8 ( ) Poverty Index = Family income / poverty threshold adjusted by family size. (Poverty defined as poverty: income ratio < 1)
25 Pooled Sensitivity & Specificity of IGRAs and TST Test Sensitivity (95% CI) Specificity (95% CI) QuantiFERON- Gold QuantiFERON- Gold In-Tube 78 (72-80) 99 (98-100) * 70 (63-78) Ann Intern Med 2008;149: (94-98) ** T-SPOT.TB 90 (86-93) 93 (86-100) Tuberculin Skin Test 77 (71-82) 97 (95-99)* Pooled results for QFN-Gold and QFN-GIT * Non-BCG vaccinated, ** BCG vaccinated 59 (46-73)**
26 Multi- and Extensively- Drug Resistant TB
27 What is MDR and XDR TB? MDR TB strains are resistant to INH and RIF (most important 1 st -line drugs) XDR TB = a subgroup of MDR strains with extensive additional resistance to Any fluoroquinolones, and One of the 2 nd -line injectable drugs (amikacin, kanamycin, capreomycin) Culture confirmed TB cases with adequate DST Results Cases with any drug resistance MDR TB XDR TB
28 MDR, XDR TB: Why be Concerned? Treatment requires mo (vs 6 8 mo) Relapse rates ~30-40% (vs 2-3%) Prolonged infectiousness Adverse events common (fewer with FLDs) Higher costs (> 100-fold increase) High mortality
29 Effect of Rifampin Duration and Drug Resistance on Treatment Outcomes Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial Drug resistance and tuberculosis treatment outomes: systematic review and meta-analysis. Ann Int Med 2008;149:
30 TB Treatment Outcomes, by Selected Drug Resistance Patterns, Latvia, * Cure Completion Death Default Failed HIV+ HR+FQ+INJ All MDRTB Percent * Leimane V, et al. First Global XDR TB Task Force Meeting. Oct 9, 2006 (from N = 820 evaluated)
31 Global Estimate of MDR TB 490,000 (95% CI, 455, ,215) incident cases in % (95% CI, 4.6% 6.0%) of all TB cases notified in 2006 Based on 138 settings surveyed in 116 countries between
32 % MDR TB Among New and Previously Treated Patients, by Region Source: WHO Anti-Tuberculosis Drug Resistance in the World, 4th Global Report. WHO/HTM/TB/ New Patients MDR-TB among New Retreatment Patients Global Africa Americas Eastern Mediterranean Eastern Europe Central and Western Europe South East Asia Western Pacific MDR %
33
34 XDR TB in KZN: Patient Characteristics* Characteristics (53 XDR TB Pts.) No. (%) No prior TB treatment (n=47) 26 ( 55) Prior hospitalization [last 2 yrs] (n=42) 28 ( 67) Previous TB treatment (n=47) Cured or completed 14 ( 30) Failure or default 7 ( 15) HIV infection (n=44) 44 (100) Dead: includes 15 (34%) on ARVs 52 ( 98) Identical genotype (n=46) 39 ( 85) * Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:
35 No. Cases Primary MDR TB United States, * No. of Cases Year * Provisional data, not for citation Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin. Percentage Percent
36 Primary MDR TB in U.S.-born and Foreign-born Persons, U.S., * 3 % Resistant U.S.-born Foreign-born * Provisional data, not for citation Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin.
37 XDR TB Cases, United States, * Total XDR TB Cases Year *2007 Unpublished provisional data, not for citation
38 XDR TB Cases by State of Residence, United States, * States (and City) No. (%) Cases New York City 16 ( 33) California 11 ( 23) New York State 8 ( 17) New Jersey 3 ( 6) NV, TX (2 each) 4 ( 8) Six other states (1 each) 6 ( 13) Total 48 (100) 79% * Based on Initial DST results; residence N/A for 2 cases
39 Diagnosing MDR and XDR TB: Requires Heightened Index of Suspicion
40 Diagnostic Laboratory Needs
41
42 Antimicrobial Agents Chemotherapy 2005;49:3192-7: Journal Clinical Microbiology 2006;44: Clinical Infectious Diseases 2007;44:418-23
43 Examples of Rapid Drug Resistance Methods GenoType Test INNO-LiPA Rif.TB MTBDR Company Hain Lifescience Innogenetics M. tuberculosis detection Yes Yes Detection RMP resistance Yes Yes Detection INH resistance Yes No Strip Assay Yes Yes DNA basis: PCR Yes Yes Direct assay No Yes (modified version) RMP resistance:rpob gene Yes Yes INH resistance:katg gene Yes No
44 WHO Expert Panel on Line Probe assays. May 2008
45
46 TB Clinical Development Pipeline Compound Development Stage Sponsor / Coordinator Gatifloxacin Moxifloxacin Diarylquinoline TMC207 Nitroimidazo-oxazole OPC Nitroimidazole PA-824 Pyrrole LL-3858 Phase III Phase II / III Early Bactericidal Activity Early Bactericidal Activity Phase I Phase I EC / OFLOTUB Consortium; IRD*; WHO TDR ο ; Lupin Ltd. Bayer; TB Alliance; CDC ; University College of London; Johns Hopkins University Johnson & Johnson (Tibotec) Otsuka Pharmaceutical Co., Ltd. TB Alliance Lupin Ltd. Novel compounds, highlighted in blue boxes, are active against MDR/XDR TB * Institut de Recherche pour le Developement ο World Health Organization, Tropical Disease Research Centers for Disease Control and Prevention
47 Why Control TB and Drug Resistance? Reduce personal suffering and death Protect others public health benefit
48 Technical Tools for TB Control
49 "Insanity is doing the same thing over and over again and expecting different results." - Albert Einstein
50 Acknowledgements National TB Controllers Association State and Local Healthdepartment TB Programs and Laboratories APHL Federal TB Task Force Global Stop TB Partnership OGAC/PEPFAR Treatment Action Group USAID WHO Stop TB Department Global XDR TB Task Force FIND, Global Alliance DTBE Staff (HQ, Field)
51 Genotype and phenotype correlation in 250 clinical M. tuberculosis isolates from Hong Kong.
Chapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States... 3 TB Disease Trends in the United
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationGlobal, National, Regional
Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology
More informationGlobal, National, Regional
Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology
More information4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB
Sindy M. Paul, MD, MPH, FACPM May 1, 2012 The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB morbidity, including resistance Identifying people
More informationTB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology
TB EPIDEMIOLOGY TB Clinical Intensive Course Curry International Tuberculosis Center September 30, 2015 Varsha Nimbal, MPH Tuberculosis Control Branch California Department of Public Health 1 Outline TB
More informationResponding to a TB Event Bismarck, North Dakota June 24-25, 2008
Responding to a TB Event Bismarck, North Dakota June 24-25, 2008 TB Epidemiology: Global and State Lynelle Phillips, RN, MPH June 24, 2008 TB Epidemiology Global and State Lynelle Phillips RN MPH Nurse
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationThe American Experience with TB Elimination
Reaching the Goal of TB Elimination by 2035 March 3, 2015 The American Experience with TB Elimination John Jereb, M.D. Medical officer Division of Tuberculosis Elimination National Center for HIV/AIDS,
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTuberculosis Epidemiology
Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline
More informationTB trends and TB genotyping
Management of a TB Contact Investigation for Public Health Workers Albuquerque, NM October 1, 214 TB trends and TB genotyping Marcos Burgos MD October 1, 214 Marcos Burgos, MD has the following disclosures
More informationANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012
ANNUAL TUBERCULOSIS REPORT OREGON 211 Oregon Health Authority Public Health Division TB Program November 212 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-211... page
More informationThe Epidemiology of Tuberculosis in Minnesota,
The Epidemiology of Tuberculosis in Minnesota, 2011 2015 Minnesota Department of Health Tuberculosis Prevention and Control Program (651) 201-5414 Tuberculosis surveillance data for Minnesota are available
More informationWhat can be done against XDR-TB?
What can be done against XDR-TB? Dr Matteo Zignol Stop TB Dep. World Health Organization Geneva 16 th Swiss Symposium on tuberculosis Münchenwiler, 22 March 2007 XDR-TB Extensive Drug Resistance XDR =
More informationDisclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012
Disclosures TB and CoMorbidities Challenges and Opportunities E. Jane Carter, M.D. Associate Professor of Medicine Alpert School of Medicine, Brown University Providence, Rhode Island No financial disclosures
More informationSubstance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Epidemiology of Substance Abuse and Tuberculosis: Where is the Problem? Mary Long, MPSH; Heartland Phillip Lindsey, MD; OK State
More informationDrug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye
Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationAnnual Tuberculosis Report Oregon 2007
Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page
More informationResearch in Tuberculosis: Translation into Practice
Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty
More informationThe Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction
The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationThe epidemiology of tuberculosis
The epidemiology of tuberculosis Tuberculosis Workshop Shanghai, 12-22 May 28 Philippe Glaziou World Health Organization Outline Epidemiology refresher Estimates of tuberculosis disease burden Notifications
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationTuberculosis in Chicago 2007
City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease
More informationExpanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination
IUATLD North American Region Conference February 24, 2017 Vancouver, BC Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationTuberculosis in Alameda County, 2009
Tuberculosis in Alameda County, 29 Alameda County Public Health Department Tuberculosis Overview Tuberculosis (TB) is a communicable disease caused by the bacteria Mycobacterium tuberculosis. TB is spread
More informationFailure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources
Failure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources Sustaining Public Health Capacity in an Age of Austerity Forum on Microbial Threats Board on Global
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationI. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %
San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7
More informationThe Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination
Four Corners TB and HIV Conference November 3, 2015 Durango, CO The Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationEpidemiology of TB: A Local and National Overview
Epidemiology of TB: A Local and National Overview Sonal S. Munsiff, MD Director, Bureau of Tuberculosis Control NYC Department of Health and Mental Hygiene Medical Officer, DTBE, CDC February 4, 24 Tuberculosis
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationGlobal TB Burden, 2016 estimates
TUBERCULOSIS EPIDEMIOLOGY LOCAL, STATE, NATIONAL, GLOBAL Office of Communicable Disease Epidemiology Global TB Burden, 216 estimates Total TB Estimated number of TB cases 1.4 million 14 per 1, Estimated
More informationPediatric Tuberculosis in Los Angeles County: An Update
Pediatric Tuberculosis in Los Angeles County: An Update Julie Higashi, MD PhD Director, Tuberculosis Control Program March 2, 2019 0 Pediatricians will be the driving force of TB elimination in California
More informationState of the State in TB Control
State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding NIH (grant)
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More information2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges
Outline of what it will take Tuberculosis Elimination 25: Global and Local Challenges Anne Fanning, MD November 9, 211 21 global TB trends, goals How DOTS happens at country level - an exercise New strategies
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Epidemiology Robert Petrossian July 18, 2012 Robert Petrossian has the following disclosures to make: No conflict of interests No relevant
More informationThe Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University
The Elimination of Tuberculosis Richard E. Chaisson, MD Center for TB Research Center for AIDS Research Johns Hopkins University Disclosures Spouse owns Merck stock Consultant: Merck Research funding:
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationEpidemiology of Tuberculosis Denver TB Course
Epidemiology of Tuberculosis Denver TB Course Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More information2008 Tuberculosis Report
2008 Tuberculosis Report County of Sacramento Department of Health and Human Services Division of Public Health Page 1 Table of Contents Figure 1. Tuberculosis Incidence Rates, County of Sacramento Vs
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationTB in Foreign Born and High Risk Populations
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 TB in Foreign Born and High Risk Populations John J. Nava, M.D. December 9, 2009 Tuberculosis in High Risk Populations and the Foreign Born
More informationGlobal Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics
Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948
More informationTuberculosis in Alameda County, 2014 Alameda County Public Health Department
Tuberculosis in Alameda, 214 Alameda Public Health Department Tuberculosis (TB) is a preventable and curable disease that remains one of the leading causes of death worldwide. TB is a communicable disease
More informationPrimer on Tuberculosis (TB) in the United States
Primer on Tuberculosis (TB) in the United States The purpose of this primer is to provide instructors who have no prior background in TB research or clinical care with basic knowledge that they may find
More informationSubstance Abuse and Tuberculosis Springfield, IL April 27, 2011
5/6/2011 Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Epidemiology of Substance Abuse and Tuberculosis: Where is the Problem? Debra Stephens, RN, BSN, MPH April 27, 2011 Debra Stephens,
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationTB Transmission, Pathogenesis & Infection Control
TB Transmission, Pathogenesis & Infection Control Bradley Allen, MD, PhD, FACP, FIDSA. 2014 MFMER slide-1 Disclosures Medical Consultant, TB Control Program Indiana State Department of Health Past clinical
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Summary Volume 13, Issue 1 February, 2014 Tuberculosis in Yakima County The rate of active tuberculosis (TB) in Yakima County has declined by about two-thirds over the past
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationArizona Annual Tuberculosis Surveillance Report
Arizona Annual Tuberculosis Surveillance Report 2014 Table of Contents I. Executive Summary 1 II. Case Rates 3 III. Cases and Case Rates by Race and Ethnicity 4 IV. Cases by Gender 4 V. Cases and Case
More informationTuberculosis Elimination
Tuberculosis Elimination Where We ve Been, Where We re Going Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination Centers for Disease Control and Prevention Disclosures / Disclaimer
More informationAddressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is
Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is Yale AIDS Program Section of Infectious Diseases Yale University School of Medicine Sheela Shenoi MD MPH September 20, 2012
More informationTuberculosis in Alameda County, 2012
Tuberculosis in Alameda County, 212 Alameda County Public Health Department Tuberculosis Overview Tuberculosis (TB) is a preventable and curable disease that remains one of the leading causes of death
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationHIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008
Tuberculosis Updates for Clinicians San Antonio, Texas November 13, 2008 HIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008 HIV as a Risk Factor for TB Tuberculosis Update for the Clinician
More informationCore Curriculum on Tuberculosis: What the Clinician Should Know
Core Curriculum on Tuberculosis: What the Clinician Should Know Sixth Edition 2013 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination 1 Chapters
More informationThe emerging threat of multidrug resistant TB: Global and local challenges and solutions
Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTransmission of XDR TB
Transmission of XDR TB Neel Gandhi, MD Tugela Ferry Care & Research Collaboration (TF CARES) Albert Einstein College of Medicine November 5, 2008 TF CARES Tugela Ferry Care and Research Collaboration Background
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More information2014 Annual Report Tuberculosis in Fresno County. Department of Public Health
214 Annual Report Tuberculosis in Fresno County Department of Public Health www.fcdph.org Tuberculosis (TB) is a common communicable disease caused by the bacterium Mycobacterium tuberculosis and occasionally
More informationHaley Blake Sage Nagai, MPH. Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic
Haley Blake Sage Nagai, MPH Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic Discuss the prevalence of tuberculosis in Clark County Describe factors influencing
More informationWASHINGTON STATE COMMUNICABLE DISEASES OF PUBLIC HEALTH SIGNIFICANCE FOR THE CIVIL SURGEON
WASHINGTON STATE COMMUNICABLE DISEASES OF PUBLIC HEALTH SIGNIFICANCE FOR THE CIVIL SURGEON SCOTT LINDQUIST MD MPH WASHINGTON STATE DEPARTMENT OF HEALTH STATE EPIDEMIOLOGIST FOR COMMUNICABLE DISEASES FOREIGN-BORN
More informationContact Investigation San Antonio, Texas January 14-15, 2013
Contact Investigation San Antonio, Texas January 14-15, 2013 Detecting and Handling a TB Outbreak Jessica Quintero, BAAS January 15, 2013 Jessica Quintero, BAAS has the following disclosures to make: No
More informationTuberculosis in Chicago 2006
Chicago Department of Public Health May 27 Communicable Disease Information Tuberculosis in Chicago 26 City of Chicago Richard M. Daley, Mayor Department of Public Health Terry Mason, MD, FACS Commissioner
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationMultidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area
Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014
TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationTB Laboratory for Nurses
TB Laboratory for Nurses Shea Rabley, RN, MN Consultant Mayo Clinic Center for Tuberculosis 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Participants will be able to: 1. Name 2 safety
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationDrug resistance TB in People Living with HIV: research questions and priorities.
Drug resistance TB in People Living with HIV: research questions and priorities. Haileyesus Getahun, MD, PhD. Stop TB Department World Health Organisation Geneva, Switzerland Outline of presentation Definition
More informationLaboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationNew Tuberculosis Guidelines. Jason Stout, MD, MHS
New Tuberculosis Guidelines Jason Stout, MD, MHS Two New Sets of Guidelines Treatment of Drug-Susceptible Tuberculosis Clinical Infectious Diseases 2016; 63(7): e147-e195 Diagnosis of Tuberculosis in Adults
More informationTB BASICS: PRIORITIES AND CLASSIFICATIONS
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.
More informationTB in California: Costs, Transmission, and Selecting from the Latent Pool
TB in California: Costs, Transmission, and Selecting from the Latent Pool Pennan Barry, MD, MPH Tuberculosis Control Branch California Department of Public Health California Tuberculosis Controller s Association
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationDetection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges
Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationControlling Vaccine Preventable Diseases in the US and Global Immunization Efforts
Controlling Vaccine Preventable Diseases in the US and Global Immunization Efforts Anne Schuchat, MD RADM, US Public Health Service Assistant Surgeon General Director, National Center for Immunization
More informationThe Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer
The Public Health Impact of TB in the Correctional System Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer The Public Health Impact of TB in the Correctional System
More information